{
  "id": 10236156,
  "title": "FDA Maintains U.S. Enrollment Hold On Newron's Phase 3 ENIGMA-TRS 2 Schizophrenia Study",
  "url": "https://urgent.news/2026/09/27/fda-maintains-u-s-enrollment-hold-on-newrons-phase-3-enigma-trs-2",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-27T14:40:20.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/fda-maintains-us-enrollment-hold-newrons-phase-3-enigma-trs-2-schizophrenia-study"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Newron Pharmaceuticals (NP5.DE, NWRN.SW) said the U.S. Food and Drug Administration (FDA) has informed the company that a hold on the enrollment of new patients at U.S. sites participating in the Phase 3 ENIGMA-TRS 2 study of evenamide will remain in place.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}